BTG plc
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BTG plc
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Biopharma M&A Volume, Value Bounced Back Significantly In Q4
Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Biocompatibles International plc
- CellMed
- Ekos Corporation
- Galil Medical, Inc.
- Novate Medical Ltd.
- PneumRx Inc.
- Protherics PLC
- Roxwood Medical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice